Erectile dysfunction has a close association with coronary heart disease. Apolipoprotein (Apo) A1, A/B, and Apo B are predictive factors for coronary heart disorders. Thus, the study aims to understand the link between apolipoproteins and erectile dysfunction.
The study covered 152 ED individuals and 39 normal individuals undergoing a fasting blood test for the apolipoprotein. The study used IIEF-5 for determining the ED severity. ROC curve analysis helped to identify the Apolipoprotein cutoff value. A questionnaire was also given to the individuals before and after the treatment. Other lipid profile indicators like total cholesterol and free fatty acids were also taken into consideration.
Patients got grouped into no ED, mild, mild-moderate, and moderate-severe cases (20.4%, 30.8%, 18.8%, and 30.4%). Those who had severe ED had reduced Apolipoprotein A and Apo A/Apo B levels. Apo B was higher in those with severe conditions. ROC curve showed that Apo A/Apo B has a medium diagnostic factor (0.743) for calculating the ED risk. For moderate to severe cases, Apo B, A, and A/B had a medium diagnostic effect (0.759, 0.703, and 0.808).
The study proved that Apo A, Apo B, and Apo A/Apo B are essential markers for assessing ED risk. These factors would assist cardiologists to assess ED in patients with coronary heart disease.
Ref url: https://www.jsm.jsexmed.org/article/S1743-6095(20)31068-7/fulltext
